Pfizer announced positive progression-free survival results from BREAKWATER trial Cohort 3, showing BRAFTOVI combined with cetuximab and FOLFIRI achieves statistically significant and clinically meaningful progression-free survival improvement compared to chemotherapy alone in previously untreated BRAF V600E-mutant metastatic colorectal cancer patients.
Eli Lilly’s Retevmo (selpercatinib) has shown promising results as an adjuvant therapy for early-stage lung cancer. The Phase 3 LIBRETTO-432 trial revealed that Retevmo adjuvant therapy significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer (NSCLC), marking a breakthrough for this rare molecular subtype affecting 1-2% of lung cancer cases.
In a landmark announcement, Roche revealed that Gazyva (obinutuzumab) met its primary endpoint in the phase III MAJESTY trial for primary membranous nephropathy treatment. The trial data demonstrates superior clinical outcomes compared to tacrolimus, positioning Gazyva as a transformative therapy for patients with this chronic autoimmune kidney condition. With nearly 88,000 affected patients in the EU and over 96,000 in the US, primary membranous nephropathy represents a significant unmet medical need. Gazyva phase III results show the potential to become the first FDA and EMA-approved therapy specifically for this indication. The positive MAJESTY trial outcomes highlight Gazyva’s mechanism deep tissue B cell depletion via anti-CD20 targeting as an effective approach to halting disease progression and preserving kidney function in primary membranous nephropathy patients.
Groundbreaking data from the KALOS and LOGOS trials reveal that Breztri (BGF) triple-therapy significantly outperforms standard dual-combination inhalers for uncontrolled asthma. Published in The Lancet Respiratory Medicine, the study confirms a 76mL improvement in lung function and a meaningful reduction in severe exacerbations, signaling a potential shift in the global standard of care.
Final data from the Phase III ALIGN study reveals that Vanrafia® (atrasentan) effectively slows eGFR decline in IgAN patients, even when combined with SGLT2 inhibitors. Novartis moves toward traditional regulatory approval in 2026.
Pfizer’s investigational “ultra-long-acting” GLP-1 receptor agonist, PF-08653944, showed robust 12.3% weight loss in its Phase 2b VESPER-3 study. Transitioning from weekly to a once-monthly injection, the drug maintained high efficacy and tolerability, positioning Pfizer as a major competitor in the 2026 obesity drug market.
A landmark real-world analysis revealed that patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with Erleada® (apalutamide) saw a 51% lower risk of death compared to those treated with darolutamide. This data marks a significant breakthrough for patients seeking effective, “chemo-free” treatment options.
India’s Eyestem Research advances to Phase 2 clinical trials for Eyecyte-RPEâ„¢ following stellar Phase 1 results that showed significant vision restoration. As a scalable “off-the-shelf” solution for dry AMD, this therapy represents a major leap in regenerative medicine and a potential global cure for Geographic Atrophy.
Roche has unveiled breakthrough Phase II data for its obesity candidate, CT-388, showing a 22.5% reduction in body weight over 48 weeks. With nearly 73% of pre-diabetic patients returning to normal glucose levels, Roche is fast-tracking the drug into Phase III Enith trials to challenge the metabolic health market.
AbbVie and Genmab have announced significant topline results from the pivotal Phase 3 EPCORE® DLBCL-1 trial. The study marks a clinical milestone as the first Phase 3 trial to demonstrate a statistically significant improvement in progression-free survival (PFS) for a CD3xCD20 bispecific antibody monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
